SMN2 and spinal muscular atrophy: For example, nusinersen—a phosphorothioate (PS) ASO with 2′-O-methoxyethyl (2′-O-MOE) modifications—was designed to induce exon 7 inclusion in SMN2 and received FDA approval for the treatment of spinal muscular atrophy.33